ovarian cancer

[Journal of Clinical Investigation] Through comparative chromatin state and gene expression analyses in ovarian CSCs vs. non-CSCs, researchers identified FOXK2 as a highly expressed stemness-specific transcription factor in ovarian cancer.

[Seminars in Cancer Biology] The authors summarize the current knowledge around the effects of chemotherapy on both ECM remodeling and ECM-cell signaling and discuss the implications of these alterations on distinct mechanisms of chemoresistance.

[European Journal of Cancer] Poly (ADP ribose) polymerase (PARP) inhibitors have shown substantial efficacy in BRCA-mutated ovarian cancer for several years, and their indication has gradually been extended to other tumour locations such as breast, prostate and pancreas.

[Cancer Cell International] Expression levels of miR-630 can be used as markers for prediction of cancer course. Moreover, miR-630 can influence response to chemoradiotherapy.

[Cancer Communications] RNA sequencing of cisplatin-resistant and -sensitive ovarian cancer organoids was performed, followed by detection of the expression level of fibrillin-1 in organoids and clinical specimens of ovarian cancer.

[Cell Cycle] Scientists investigated the effect of LINC01234 on the differentiation and self-renewal of ovarian cancer stem cells through adsorption of microRNA-27b-5p to target sirtuins 5 (SIRT5).